Related Experiment Video
Updated: Jul 3, 2026
08:54
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
Published on: February 17, 2023
Design of anticancer prodrugs for reductive activation
1Department of Pharmaceutical Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Medicinal Research Reviews
|August 9, 2008
Summary
Researchers are developing anticancer prodrugs activated by reductive enzymes to target tumors specifically. This strategy aims to enhance cancer treatment effectiveness while minimizing side effects through advanced medicinal chemistry.
Area of Science:
- Medicinal Chemistry
- Oncology
- Drug Development
Background:
- Anticancer prodrugs aim to improve cancer therapy by targeting tumor cells specifically, reducing systemic side effects.
- Significant progress has been made in developing prodrugs activated by reductive processes over the past two decades.
- Hypoxic tumor tissues often overexpress endogenous reductive enzymes, making them a target for reductively activated prodrugs.
Purpose of the Study:
- To review the medicinal chemistry of reductively activated anticancer prodrugs.
- To discuss design principles, structure-activity relationships, and activation mechanisms.
- To highlight the potential of these prodrugs in cancer treatment.
Main Methods:
- Focus on functional groups like quinones, nitroaromatics, N-oxides, and metal complexes in prodrug design.
- Exploration of both endogenous and exogenous reductive enzyme activation strategies.
- Review of structure-activity relationships and drug release mechanisms.
Main Results:
- Various classes of reductively activated prodrugs have been designed and studied.
- Prodrugs can be activated by endogenous enzymes or via exogenous enzyme delivery (e.g., antibody fusion, gene delivery).
- Several reductively activated prodrugs are currently in clinical trials, indicating promising therapeutic potential.
Conclusions:
- Reductively activated prodrugs offer a targeted approach to cancer therapy.
- Medicinal chemistry plays a crucial role in optimizing the design and activation of these agents.
- Continued research and clinical trials are essential for the advancement of this therapeutic strategy.
Related Concept Videos
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:27Phase I Reactions: Reductive Reactions
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:38Preparation of Amines: Reductive Amination of Aldehydes and Ketones
Carbonyl compounds and primary amines undergo reductive amination first to produce imines, followed by secondary amines in the same reaction mixture, using selective reducing agents like sodium cyanoborohydride or sodium triacetoxyborohydride. Reductive amination produces different degrees of substitution of amines depending on the starting amine substrate.
02:17Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
Catalytic hydrogenation of alkenes is a transition-metal catalyzed reduction of the double bond using molecular hydrogen to give alkanes. The mode of hydrogen addition follows syn stereochemistry.
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
01:14Drug Metabolism: Phase II Reactions
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...